Evidence of securin-mediated resistance to gefitinib-induced apoptosis in human cancer cells

Chemico-Biological Interactions

Volumn 203, Issue 2, 2013, Pages 412-422

  Yu, Sheng Yi ^a   Liu, Huei Fang ^a   Wang, Su Pei ^a   Chang, Chia Ching ^a   Tsai, Chuan Mei ^a   Chao, Jui I ^a  

^a NATIONAL CHIAO TUNG UNIVERSITY   (Taiwan)

Author keywords

Apoptosis; Cancer cells; EGFR; Gefitinib; Securin

Indexed keywords

CASPASE 3; CYTOCHROME C; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; SECURIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; ENZYME ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; SECURIN GENE; SIGNAL TRANSDUCTION; WILD TYPE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; NEOPLASM PROTEINS; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN STABILITY; PROTEOLYSIS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84876004459     PISSN: 00092797     EISSN: 18727786     Source Type: Journal    
DOI: 10.1016/j.cbi.2013.03.011     Document Type: Article

References (47)

1. A. Citri, and Y. Yarden EGF-ERBB signalling: towards the systems level Nat. Rev. Mol. Cell Biol. 7 2006 505 516
2. M. Sibilia, R. Kroismayr, B.M. Lichtenberger, A. Natarajan, M. Hecking, and M. Holcmann The epidermal growth factor receptor: from development to tumorigenesis Differentiation 75 2007 770 787
3. J.R. Grandis, and J.C. Sok Signaling through the epidermal growth factor receptor during the development of malignancy Pharmacol. Ther. 102 2004 37 46
4. J.G. Paez, P.A. Janne, J.C. Lee, S. Tracy, H. Greulich, S. Gabriel, P. Herman, F.J. Kaye, N. Lindeman, T.J. Boggon, K. Naoki, H. Sasaki, Y. Fujii, M.J. Eck, W.R. Sellers, B.E. Johnson, and M. Meyerson EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
5. P.R. Dutta, and A. Maity Cellular responses to EGFR inhibitors and their relevance to cancer therapy Cancer Lett. 254 2007 165 177
6. G. Lurje, and H.J. Lenz EGFR signaling and drug discovery Oncology 77 2009 400 410
7. F. Ciardiello, and G. Tortora EGFR antagonists in cancer treatment N. Engl. J. Med. 358 2008 1160 1174
8. M. Ono, A. Hirata, T. Kometani, M. Miyagawa, S. Ueda, H. Kinoshita, T. Fujii, and M. Kuwano Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation Mol. Cancer Ther. 3 2004 465 472
9. F. Ciardiello, R. Caputo, R. Bianco, V. Damiano, G. Pomatico, S. De Placido, A.R. Bianco, and G. Tortora Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor Clin. Cancer Res. 6 2000 2053 2063
10. F.M. Sirotnak, M.F. Zakowski, V.A. Miller, H.I. Scher, and M.G. Kris Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase Clin. Cancer Res. 6 2000 4885 4892
11. S. Huang, S. Benavente, E.A. Armstrong, C. Li, D.L. Wheeler, and P.M. Harari P53 modulates acquired resistance to EGFR inhibitors and radiation Cancer Res. 71 2011 7071 7079
12. D. Jackman, W. Pao, G.J. Riely, J.A. Engelman, M.G. Kris, P.A. Janne, T. Lynch, B.E. Johnson, and V.A. Miller Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer J. Clin. Oncol. 28 2010 357 360
13. D.L. Wheeler, E.F. Dunn, and P.M. Harari Understanding resistance to EGFR inhibitors-impact on future treatment strategies Nat. Rev. Clin. Oncol. 7 2010 493 507
14. J.A. Engelman, and P.A. Janne Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer Clin. Cancer Res. 14 2008 2895 2899
15. C.H. Yun, K.E. Mengwasser, A.V. Toms, M.S. Woo, H. Greulich, K.K. Wong, M. Meyerson, and M.J. Eck The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP Proc. Natl. Acad. Sci. USA 105 2008 2070 2075
16. H. Zou, T.J. McGarry, T. Bernal, and M.W. Kirschner Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis Science 285 1999 418 422
17. A. Dominguez, F. Ramos-Morales, F. Romero, R.M. Rios, F. Dreyfus, M. Tortolero, and J.A. Pintor-Toro Hpttg, a human homologue of rat pttg, is overexpressed in hematopoietic neoplasms, Evidence for a transcriptional activation function of hPTTG Oncogene 17 1998 2187 2193
18. G. Vlotides, T. Eigler, and S. Melmed Pituitary tumor-transforming gene: physiology and implications for tumorigenesis Endocr. Rev. 28 2007 165 186
19. J. Mei, X. Huang, and P. Zhang Securin is not required for cellular viability, but is required for normal growth of mouse embryonic fibroblasts Curr. Biol. 11 2001 1197 1201
20. P.V. Jallepalli, I.C. Waizenegger, F. Bunz, S. Langer, M.R. Speicher, J.M. Peters, K.W. Kinzler, B. Vogelstein, and C. Lengauer Securin is required for chromosomal stability in human cells Cell 105 2001 445 457
21. F. Salehi, K. Kovacs, B.W. Scheithauer, R.V. Lloyd, and M. Cusimano Pituitary tumor-transforming gene in endocrine and other neoplasms: a review and update Endocr. Relat. Cancer 15 2008 721 743
22. X. Zhang, G.A. Horwitz, T.R. Prezant, A. Valentini, M. Nakashima, M.D. Bronstein, and S. Melmed Structure, expression, and function of human pituitary tumor-transforming gene (PTTG) Mol. Endocrinol. 13 1999 156 166
23. A.P. Heaney, R. Singson, C.J. McCabe, V. Nelson, M. Nakashima, and S. Melmed Expression of pituitary-tumour transforming gene in colorectal tumours Lancet 355 2000 716 719
24. C. Solbach, M. Roller, C. Fellbaum, M. Nicoletti, and M. Kaufmann PTTG mRNA expression in primary breast cancer: a prognostic marker for lymph node invasion and tumor recurrence Breast 13 2004 80 81
25. S.S. Kakar, and M.T. Malik Suppression of lung cancer with siRNA targeting PTTG Int. J. Oncol. 29 2006 387 395
26. R. Puri, A. Tousson, L. Chen, and S.S. Kakar Molecular cloning of pituitary tumor transforming gene 1 from ovarian tumors and its expression in tumors Cancer Lett. 163 2001 131 139
27. J.I. Chao, S.H. Hsu, and T.C. Tsou Depletion of securin increases arsenite-induced chromosome instability and apoptosis via a p53-independent pathway Toxicol. Sci. 90 2006 73 86
28. J.I. Chao, and H.F. Liu The blockage of survivin and securin expression increases the cytochalasin B-induced cell death and growth inhibition in human cancer cells Mol. Pharmacol. 69 2006 154 164
29. W.S. Chen, Y.C. Yu, Y.J. Lee, J.H. Chen, H.Y. Hsu, and S.J. Chiu Depletion of securin induces senescence after irradiation and enhances radiosensitivity in human cancer cells regardless of functional p53 expression Int. J. Radiat. Oncol. Biol. Phys. 77 2010 566 574
30. T. Hamid, M.T. Malik, and S.S. Kakar Ectopic Expression of PTTG1/securin promotes tumorigenesis in human embryonic kidney cells Mol. Cancer 4 2005 3
31. K. Boelaert, C.J. McCabe, L.A. Tannahill, N.J. Gittoes, R.L. Holder, J.C. Watkinson, A.R. Bradwell, M.C. Sheppard, and J.A. Franklyn Pituitary tumor transforming gene and fibroblast growth factor-2 expression: potential prognostic indicators in differentiated thyroid cancer J. Clin. Endocrinol. Metab. 88 2003 2341 2347
32. K. Talvinen, H. Karra, S. Hurme, M. Nykanen, A. Nieminen, J. Anttinen, T. Kuopio, and P. Kronqvist Securin promotes the identification of favourable outcome in invasive breast cancer Br. J. Cancer 101 2009 1005 1010
33. S.T. Avoranta, E.A. Korkeila, H.R. Minn, K.J. Syrjanen, S.O. Pyrhonen, and J.T. Sundstrom Securin identifies a subgroup of patients with poor outcome in rectal cancer treated with long-course (chemo) radiotherapy Acta Oncol. 50 2011 1158 1166
34. H. Karra, R. Pitkanen, M. Nykanen, K. Talvinen, T. Kuopio, M. Soderstrom, and P. Kronqvist Securin predicts aneuploidy and survival in breast cancer Histopathology 60 2012 586 596
35. G. Vlotides, M. Cruz-Soto, T. Rubinek, T. Eigler, C.J. Auernhammer, and S. Melmed Mechanisms for growth factor-induced pituitary tumor transforming gene-1 expression in pituitary folliculostellate TtT/GF cells Mol. Endocrinol. 20 2006 3321 3335
36. J. Tfelt-Hansen, S. Yano, S. Bandyopadhyay, R. Carroll, E.M. Brown, and N. Chattopadhyay Expression of pituitary tumor transforming gene (PTTG) and its binding protein in human astrocytes and astrocytoma cells: function and regulation of PTTG in U87 astrocytoma cells Endocrinology 145 2004 4222 4231
37. S.H. Yu, P.M. Yang, C.W. Peng, Y.C. Yu, and S.J. Chiu Securin depletion sensitizes human colon cancer cells to fisetin-induced apoptosis Cancer Lett. 300 2011 96 104
38. Y. Shi Mechanisms of caspase activation and inhibition during apoptosis Mol. Cell 9 2002 459 470
39. D.K. Miller The role of the caspase family of cysteine proteases in apoptosis Semin. Immunol. 9 1997 35 49
40. M. Poppe, C. Reimertz, H. Dussmann, A.J. Krohn, C.M. Luetjens, D. Bockelmann, A.L. Nieminen, D. Kogel, and J.H. Prehn Dissipation of potassium and proton gradients inhibits mitochondrial hyperpolarization and cytochrome c release during neural apoptosis J. Neurosci. 21 2001 4551 4563
41. A. Gross, J.M. McDonnell, and S.J. Korsmeyer BCL-2 family members and the mitochondria in apoptosis Genes Dev. 13 1999 1899 1911
42. P.W. Hsiao, C.C. Chang, H.F. Liu, C.M. Tsai, T.H. Chiu, and J.I. Chao Activation of p38 mitogen-activated protein kinase by celecoxib oppositely regulates survivin and gamma-H2AX in human colorectal cancer cells Toxicol. Appl. Pharmacol. 222 2007 97 104
43. S. Bates, and K.H. Vousden P53 in signaling checkpoint arrest or apoptosis Curr. Opin. Genet. Dev. 6 1996 12 18
44. A.J. Levine P53, the cellular gatekeeper for growth and division Cell 88 1997 323 331
45. L.J. Hofseth, S.P. Hussain, and C.C. Harris P53: 25 years after its discovery Trends Pharmacol. Sci. 25 2004 177 181
46. J.A. Bernal, R. Luna, A. Espina, I. Lazaro, F. Ramos-Morales, F. Romero, C. Arias, A. Silva, M. Tortolero, and J.A. Pintor-Toro Human securin interacts with p53 and modulates p53-mediated transcriptional activity and apoptosis Nat. Genet. 32 2002 306 311
47. S.J. Chiu, T.S. Hsu, and J.I. Chao Opposing securin and p53 protein expression in the oxaliplatin-induced cytotoxicity of human colorectal cancer cells Toxicol. Lett. 167 2006 122 130